tirzepatide and pancreas Acute Pancreatitis Caused by Possible pro-oncogenic effect of tirzepatide

Semaglutide is probably right for you if: You want the drug with the deepest long-term safety and cardiovascular outcomes data You have or are at high risk for cardiovascular disease (the SELECT trial data is specifically for this population) You've had significant GI issues with other medications and want to start conservatively You need something available today with a well-established clinical protocol Tirzepatide is probably right for you if: You've tried semaglutide and found the weight loss insufficient or plateaued You have insulin resistance or type 2 diabetes and want better glycemic control alongside weight loss You have metabolic-associated steatohepatitis (fatty liver disease) the MASH data is compelling You want better-than-semaglutide weight loss with a Phase 3-validated profile Retatrutide is probably right for you if: You're comfortable being an early adopter and understand you're working with Phase 2 data You have severe obesity (BMI over 40) and haven't achieved sufficient results with GLP-1 or dual agonists You have significant hepatic steatosis or high triglycerides where glucagon activity may add direct benefit You're enrolled through a supervised clinical program that can monitor the novel aspects of triple agonism One more note: none of these drugs are right for you without lab work first

However, just like most synthetic drugs, its benefits also come with risks

Taking the two tablets close together increases the amount of thyroxine you absorb, and losing weight reduces the amount of levothyroxine your body needs

SIRT1 is protective and decreased BBB permeability, whereas SIRT3 increased permeability

WE ARE NOT SELLING A PRODUCT, WE ARE SELLING A LIFESTYLE